[go: up one dir, main page]

HUT72923A - Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens - Google Patents

Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

Info

Publication number
HUT72923A
HUT72923A HU9502002A HU9502002A HUT72923A HU T72923 A HUT72923 A HU T72923A HU 9502002 A HU9502002 A HU 9502002A HU 9502002 A HU9502002 A HU 9502002A HU T72923 A HUT72923 A HU T72923A
Authority
HU
Hungary
Prior art keywords
antigens
prevention
preparation
treatment
recombinant methods
Prior art date
Application number
HU9502002A
Other languages
English (en)
Other versions
HU9502002D0 (en
HU217024B (hu
Inventor
Brian Crowe
Friedrich Dorner
Ian Livey
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of HU9502002D0 publication Critical patent/HU9502002D0/hu
Publication of HUT72923A publication Critical patent/HUT72923A/hu
Publication of HU217024B publication Critical patent/HU217024B/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9502002A 1993-04-29 1994-04-29 Immunogén OspC-antigén vakcinakészítmények a Lyme-kór megelőzésére és kezelésére, valamint eljárások ilyen antigének előállítására HU217024B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (3)

Publication Number Publication Date
HU9502002D0 HU9502002D0 (en) 1995-08-28
HUT72923A true HUT72923A (en) 1996-06-28
HU217024B HU217024B (hu) 1999-11-29

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502002A HU217024B (hu) 1993-04-29 1994-04-29 Immunogén OspC-antigén vakcinakészítmények a Lyme-kór megelőzésére és kezelésére, valamint eljárások ilyen antigének előállítására

Country Status (16)

Country Link
EP (1) EP0701612B1 (hu)
JP (1) JPH08509371A (hu)
AT (1) ATE162550T1 (hu)
AU (1) AU683260B2 (hu)
CA (1) CA2161534A1 (hu)
CZ (1) CZ289212B6 (hu)
DE (1) DE69408135T2 (hu)
DK (1) DK0701612T3 (hu)
ES (1) ES2114687T3 (hu)
FI (1) FI955150A (hu)
HR (1) HRP940279B1 (hu)
HU (1) HU217024B (hu)
NO (1) NO954318L (hu)
PL (1) PL178775B1 (hu)
SK (1) SK279968B6 (hu)
WO (1) WO1994025596A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
CA2253374C (en) * 1996-05-02 2004-07-20 Marianne Jartved Mathiesen Novel osp-c derived peptide fragments
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
JP3631960B2 (ja) 1998-07-31 2005-03-23 ガンダーセン ルテラン メディカル ファウンデイション インコーポレイテッド ワクチンとしてのボレリアブルグドルフェリ外部表面タンパク質c(ospc)のボレリアシダルエピトープの使用
US7060281B1 (en) 1999-06-18 2006-06-13 Research Foundation Of The State University Of New York Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
ES2298249T3 (es) 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
GB2414667A (en) 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
AU2006320246A1 (en) * 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
CA2668405C (en) * 2006-11-03 2015-05-05 Schering-Plough Ltd. Canine lyme disease vaccine
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
HU9502002D0 (en) 1995-08-28
SK279968B6 (sk) 1999-06-11
DE69408135D1 (de) 1998-02-26
PL178775B1 (pl) 2000-06-30
PL311301A1 (en) 1996-02-05
EP0701612A1 (en) 1996-03-20
NO954318D0 (no) 1995-10-27
HRP940279A2 (en) 1997-10-31
HU217024B (hu) 1999-11-29
SK134195A3 (en) 1996-05-08
CZ289212B6 (cs) 2001-12-12
WO1994025596A2 (en) 1994-11-10
ES2114687T3 (es) 1998-06-01
EP0701612B1 (en) 1998-01-21
AU683260B2 (en) 1997-11-06
CA2161534A1 (en) 1994-11-10
ATE162550T1 (de) 1998-02-15
DK0701612T3 (da) 1998-09-21
AU6722994A (en) 1994-11-21
FI955150A (fi) 1995-12-28
CZ283995A3 (en) 1996-03-13
HRP940279B1 (en) 2000-12-31
WO1994025596A3 (en) 1994-12-22
NO954318L (no) 1995-12-29
DE69408135T2 (de) 1998-06-10
FI955150A0 (fi) 1995-10-27
JPH08509371A (ja) 1996-10-08

Similar Documents

Publication Publication Date Title
HUT72923A (en) Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2001328A1 (en) Borrelia antigen
AU1955088A (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic AMP
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
DK0598816T3 (da) Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
EP1630229A3 (en) Melanoma antigens
PL325373A1 (en) Compounds and methods useful in tuberculosos immunotherapy and diagnostics
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
GR3017778T3 (en) Immunogenic complexes, in particular iscoms.
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
ES8800052A1 (es) Un procedimiento para preparar una proteina de superficie antigenica de anaplasma marginale
EP1020516A3 (en) Leptospira vaccine antigens for the prevention of leptospirosis
DE69615537D1 (en) Helicobacter pylori antigen
SE9600646D0 (sv) Vaccin
HUP0002752A2 (hu) Egy szekréciós vektor alkalmazása termékenység-szabályozásra orális vakcinálással
MX9700215A (es) Proteinas y vacunas de helicobacter.
CA2347278A1 (en) Vaccine based on attenuated haemophilus somnus

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee
MM4A Lapse of definitive patent protection due to non-payment of fees